{"created":"2023-05-15T08:55:47.056633+00:00","id":1007,"links":{},"metadata":{"_buckets":{"deposit":"4cfd0094-c63a-4784-86dc-dba4b057c410"},"_deposit":{"created_by":10,"id":"1007","owners":[10],"pid":{"revision_id":0,"type":"depid","value":"1007"},"status":"published"},"_oai":{"id":"oai:tsurumi-u.repo.nii.ac.jp:00001007","sets":["100:101:103:157"]},"author_link":["764"],"item_10007_date_8":{"attribute_name":"報告年度","attribute_value_mlt":[{"subitem_date_issued_datetime":"2020-03-31","subitem_date_issued_type":"Issued"}]},"item_10007_description_13":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：樹状細胞（DC）を用いた癌ワクチンと免疫チェックポイント阻害剤を併用した複合免疫療法の効果について検討した。In vitro実験にて癌抗原WT1に対する細胞傷害性T細胞（CTL）誘導は、抗PD-1抗体を併用することにより増強した。同系腫瘍移植マウスをWT1パルスDC及び抗PD-1抗体で治療する事により、各々単独治療と比較して強い抗腫瘍効果を認めた。協力医療機関にて、抗PD-1抗体＋癌抗原パルスDCワクチン併用療法のパイロットスタディを施行した。現在まで6例の切除不能口腔癌患者に同治療を行い経過観察中である。全例で、使用した癌抗原のうち少なくとも1種の癌抗原に特異的なCTLの誘導を確認した。","subitem_description_language":"ja","subitem_description_type":"Abstract"},{"subitem_description":"研究成果の概要（英文）：We investigated the effect of the combined immunotherapy with the cancer vaccine using dendritic cells（DC）and the immune checkpoint inhibitor. In in vitro experiment, induction of cytotoxic T lymphocytes（CTLs）against WT1, which was reported to be expressed in oral squamous cell carcinoma cells, was enhanced by the combined use of anti-PD-1 antibody. In in vivo study using syngeneic tumor-bearing mice, stronger anti-tumor effect was observed by the treatment with WT1 pulsed DC vaccine and anti-PD-1 antibody as compared with DC vaccine alone or anti-PD-1 antibody alone. We conducted a pilot study of the combination therapy with anti-PD-1 antibody + cancer antigen pulsed DC vaccine. Up to now, 6 patients with unresectable oral cancer have been treated with the same method and are under observation. In all cases, induction of CTL specific for at least one cancer antigen used was confirmed. We plan to continue expanding the number of cases.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10007_description_14":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"・2019(令和元)年度 科学研究費補助金 基盤研究(B) 研究成果報告書","subitem_description_language":"ja","subitem_description_type":"Other"},{"subitem_description":"・研究期間 (年度)：2017-04-01 – 2020-03-31","subitem_description_language":"ja","subitem_description_type":"Other"},{"subitem_description":"・研究分野：癌免疫療法","subitem_description_language":"ja","subitem_description_type":"Other"},{"subitem_description":"・研究成果の学術的意義や社会的意義 : オプジーボやキィトルーダ等の免疫チェックポイント阻害剤による癌治療効果が明らかになり癌に対する免疫療法が注目されている。しかしな、免疫チェックポイント阻害剤の治療効果は15～25％程度であり決して満足できるものではない。さらなる治療効果向上の為に癌ワクチンとの併用が期待されている。本研究結果にて、樹状細胞ワクチンと免疫チェックポイント阻害剤の併用が非常に効果的である可能性が強く示唆され、より有効な癌治療法の開発に寄与すると考えられる。","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10007_description_9":{"attribute_name":"研究課題番号","attribute_value_mlt":[{"subitem_description":"研究課題/領域番号 : 17H04410","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10007_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://kaken.nii.ac.jp/ja/grant/KAKENHI-PROJECT-17H04410/","subitem_relation_type_select":"URI"}}]},"item_10007_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2022-03-08"}],"displaytype":"detail","filename":"17H04410.pdf","filesize":[{"value":"92.0 kB"}],"format":"application/pdf","licensetype":"license_6","mimetype":"application/pdf","url":{"label":"17H04410","url":"https://tsurumi-u.repo.nii.ac.jp/record/1007/files/17H04410.pdf"},"version_id":"1d7fd811-166c-4a88-984f-423a08774dd4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"癌ワクチン","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫チェックポイント阻害剤","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"樹状細胞","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"複合免疫療法","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"口腔癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_researcher":{"attribute_name":"研究代表者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"","affiliationNameIdentifierScheme":"ISNI","affiliationNameIdentifierURI":"http://www.isni.org/isni/"}],"affiliationNames":[{"affiliationName":"","affiliationNameLang":"ja"}]}],"creatorNames":[{"creatorName":"OKAMOTO, Masato","creatorNameLang":"en"},{"creatorName":"岡本, 正人","creatorNameLang":"ja"},{"creatorName":"オカモト, マサト","creatorNameLang":"ja-Kana"}],"familyNames":[{"familyName":"OKAMOTO","familyNameLang":"en"},{"familyName":"岡本","familyNameLang":"ja"},{"familyName":"オカモト","familyNameLang":"ja-Kana"}],"givenNames":[{"givenName":"Masato","givenNameLang":"en"},{"givenName":"正人","givenNameLang":"ja"},{"givenName":"マサト","givenNameLang":"ja-Kana"}],"nameIdentifiers":[{"nameIdentifier":"764","nameIdentifierScheme":"WEKO"},{"nameIdentifier":"10243718","nameIdentifierScheme":"e-Rad","nameIdentifierURI":"https://kaken.nii.ac.jp/ja/search/?qm=10243718"},{"nameIdentifier":"764","nameIdentifierScheme":"WEKO著者ID"}]}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"複合免疫療法の開発～免疫チェックポイント阻害剤と癌ワクチン～","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"複合免疫療法の開発～免疫チェックポイント阻害剤と癌ワクチン～","subitem_title_language":"ja"},{"subitem_title":"Development of the combined immunotherapy; immune checkpoint inhibitor and cancer vaccine","subitem_title_language":"en"}]},"item_type_id":"10007","owner":"10","path":["157"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2022-03-08"},"publish_date":"2022-03-08","publish_status":"0","recid":"1007","relation_version_is_last":true,"title":["複合免疫療法の開発～免疫チェックポイント阻害剤と癌ワクチン～"],"weko_creator_id":"10","weko_shared_id":-1},"updated":"2024-08-01T08:20:50.013490+00:00"}